trending Market Intelligence /marketintelligence/en/news-insights/trending/ac7ejij6rkkftkyymhazna2 content esgSubNav
In This List

Citius Pharmaceuticals prices $10M underwritten stock offering

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Citius Pharmaceuticals prices $10M underwritten stock offering

Cranford, N.J.-based Citius Pharmaceuticals Inc. priced a $10 million offering of securities.

The specialty pharmaceutical company will offer 7,843,138 shares at $1.275 each, complete with warrants to buy up to an equal number of additional stock.

The warrants will be exercisable immediately at $1.15 per share.

Citius intends to use the proceeds for its phase 3 clinical trial of Mino-Lok for the treatment of catheter-related bloodstream infections and its phase 2b clinical trial of Hydro-Lido cream for the treatment of hemorrhoids, and also for working capital and capital expenditures.

H.C. Wainwright & Co. LLC is acting as the sole book-running manager for the offering which is expected to close by Aug. 13.